gamma-Aminobutyric acid

Engrail Therapeutics Extends Series A Financing to $64 Million

Retrieved on: 
Tuesday, August 3, 2021
Pharmaceutical, Health, Clinical trials, GABAA receptor positive allosteric modulators, Branches of biology, Neurochemistry, Life sciences, gamma-Aminobutyric acid, Pharmacology, Engrail Therapeutics, Nan Fung Life Sciences, ENGRAIL THERAPEUTICS, NAN FUNG LIFE SCIENCES

Engrail Therapeutics (Engrail) (the Company), a neuroscience company focused on the acquisition, development and commercialization of patient-centric therapies, today announced the close of a $32 million extension of its Series A financing round, which brings the total round to $64 million.

Key Points: 
  • Engrail Therapeutics (Engrail) (the Company), a neuroscience company focused on the acquisition, development and commercialization of patient-centric therapies, today announced the close of a $32 million extension of its Series A financing round, which brings the total round to $64 million.
  • Nan Fung Life Sciences (NFLS), the global investment platform of the Nan Fung Group, led this round following their leadership of the original Series A raise.
  • Engrails lead compounds are subtype-selective GABA-A modulators with compelling pharmacological profiles that possess wide ranging therapeutic utility.
  • Founded in 2019, Engrail is forging a new direction to reduce the enormous burden of diseases that impact the nervous system.

Addex and Indivior Extend Research Collaboration on GABAB Positive Allosteric Modulators - Indivior Commits $4 Million of New Funding

Retrieved on: 
Thursday, July 29, 2021
Branches of biology, Drugs, Neurochemistry, Indivior, GABAA receptor positive allosteric modulators, Allosteric regulation, gamma-Aminobutyric acid

As part of the extension, Indivior has committed $4 million of new funding to advance development of selected novel oral gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM) drug candidates discovered by Addex.

Key Points: 
  • As part of the extension, Indivior has committed $4 million of new funding to advance development of selected novel oral gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM) drug candidates discovered by Addex.
  • Excellent progress has been made in our research collaboration with Addex, said Christian Heidbreder, Chief Scientific Officer of Indivior.
  • With this new funding, Indivior has reiterated its commitment to advance this novel allosteric approach towards clinical evaluation.
  • Indivior PLC has licensed Addexs GABAB PAM program for the development of drug candidates with a focus in addiction.

FDA Clears LPCN 1154 IND Application for a Phase 2 Postpartum Depression Study

Retrieved on: 
Monday, June 14, 2021
Branches of biology, Neurochemistry, GABAA receptor positive allosteric modulators, Gába, GABAA receptor, Allosteric modulator, gamma-Aminobutyric acid, Allosteric regulation

PPD, a major depressive disorder that is under diagnosed in US, impacts approximately 1 in 7 women after giving birth.

Key Points: 
  • PPD, a major depressive disorder that is under diagnosed in US, impacts approximately 1 in 7 women after giving birth.
  • The active moiety in LPCN 1154 is an endogenous positive allosteric modulator of -aminobutyric acid ("GABAA") receptor.
  • Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148, LPCN 1154, and LPCN 1107.
  • LPCN 1154 is an oral neuro-steroid targeted for the treatment of post-partum depression.

Saniona to Present Preclinical Data on SAN711 at the 7th Congress of the European Academy of Neurology

Retrieved on: 
Tuesday, June 8, 2021
Branches of biology, Neurochemistry, Gába, Transmembrane receptors, GABAA receptor, GABA receptor, gamma-Aminobutyric acid, Allosteric regulation, Allosteric modulator

SAN711 is a first-in-class positive allosteric modulator of GABA-A 3 that was designed using Sanionas ion channel drug discovery engine.

Key Points: 
  • SAN711 is a first-in-class positive allosteric modulator of GABA-A 3 that was designed using Sanionas ion channel drug discovery engine.
  • While existing molecules target all GABA-A receptors indiscriminately, SAN711 selectively enhances the effects of GABA-A on 3 containing receptors.
  • Saniona also plans to continue to share its data on SAN711 and other preclinical programs in additional scientific and investor forums.
  • Saniona expects to begin a Phase 1 study of SAN711 in healthy volunteers in mid-2021, with data expected in early 2022.

Saniona Hosts Research and Development (R&D) Day on Proprietary Ion Channel Drug Discovery Engine and Pipeline Programs

Retrieved on: 
Thursday, May 20, 2021
Branches of biology, Neurochemistry, GABAA receptor positive allosteric modulators, Biology of obsessive–compulsive disorder, gamma-Aminobutyric acid, Neurotransmitters, Neuroscience

b'Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it hosted a virtual R&D day event, during which it discussed its ion channel drug discovery engine and proprietary IONBASE\xe2\x84\xa2 database.

Key Points: 
  • b'Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it hosted a virtual R&D day event, during which it discussed its ion channel drug discovery engine and proprietary IONBASE\xe2\x84\xa2 database.
  • The core of this engine is Saniona\xe2\x80\x99s proprietary IONBASE database, which contains structure-activity data for more than 120,000 compounds.
  • Of these, 20,000 are Saniona\xe2\x80\x99s proprietary compounds, generated over 20 years and enriched for optimal ion channel modulation.\nSAN711 is a first-in-class drug candidate that selectively enhances the effects of GABA-A on \xce\xb13 containing receptors.
  • Saniona\xe2\x80\x99s robust drug discovery engine has generated a library now consisting of more than 20,000 proprietary modulators of ion channels, a significantly untapped drug class that is scientifically validated.

Addex GABAB Positive Allosteric Modulator Demonstrates Promise in Alcohol Use Disorder

Retrieved on: 
Tuesday, February 16, 2021
Branches of biology, Receptor agonists, Neurochemistry, GABAA receptor positive allosteric modulators, Drinking culture, Sedatives, Hypnotics, General anesthetics, Alcohol, Allosteric modulator, gamma-Aminobutyric acid, Allosteric regulation

ADX71441 potently decreased binge-like drinking, reduced relapse-like drinking, and dose-dependently reduced alcohol self-administration as well as decreasing motivation to consume alcohol.

Key Points: 
  • ADX71441 potently decreased binge-like drinking, reduced relapse-like drinking, and dose-dependently reduced alcohol self-administration as well as decreasing motivation to consume alcohol.
  • Augier E. (2021) Recent Advances in the Potential of Positive Allosteric Modulators of the GABAB Receptor to Treat Alcohol Use Disorder.
  • (2014) Reduction of excessive alcohol drinking by a novel GABAB receptor positive allosteric modulator ADX71441 in mice.
  • (2017) The GABAB positive allosteric modulator ADX71441 attenuates alcohol self-administration and relapse to alcohol seeking in rats.

Addex Receives Additional $2.8 million from Indivior and Extends GABAB PAM Research Collaboration

Retrieved on: 
Monday, November 2, 2020
Branches of biology, Neurochemistry, Drugs, Enzyme kinetics, Allosteric regulation, Proteins, Indivior, gamma-Aminobutyric acid

The collaboration with Indivior covers the discovery of novel oral gamma-aminobutyric acid receptor subtype B (GABAB) positive allosteric modulator (PAM) compounds as potential therapies for multiple disease areas.

Key Points: 
  • The collaboration with Indivior covers the discovery of novel oral gamma-aminobutyric acid receptor subtype B (GABAB) positive allosteric modulator (PAM) compounds as potential therapies for multiple disease areas.
  • As part of the amended agreement, Indivior has agreed to pay Addex $2.8 million in research funding and expand the therapeutic areas where Addex has exclusivity to develop retained compounds.
  • The extension of our research collaboration and the additional funding from Indivior is a clear recognition of the potential of our allosteric modulator discovery platform and the significant achievements of our drug discovery team, said Tim Dyer, CEO of Addex.
  • Under the terms of the original agreement signed with Indivior in January 2018 , Addex received a $5 million upfront payment and has since received $5.6 million research funding.

Sage Therapeutics’ FutureCast to Provide Update on Pipeline Progression and Additional Insights into Potential of Brain Health Franchises

Retrieved on: 
Thursday, September 10, 2020
Mental health, Health, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Neuroscience, Neurochemistry, Glutamate, Molecular neuroscience, Neurotransmitters, GABAA receptor positive allosteric modulators, NMDA receptor, gamma-Aminobutyric acid

We continue to focus on areas where our early clinical data suggest the potential for meaningful patient benefit, not just incremental change.

Key Points: 
  • We continue to focus on areas where our early clinical data suggest the potential for meaningful patient benefit, not just incremental change.
  • I believe we are one of the few companies developing new chemical equity with a goal of making true advances in brain health.
  • Sage is advancing a portfolio of novel and differentiated product candidates designed to improve brain health by targeting the GABA and NMDA receptor systems.
  • Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain.

Insomnia Data 2020: US Leads in Global Insomnia Clinical Trials, Germany Leads Major European Markets and Japan Has Top Spot in Asia

Retrieved on: 
Thursday, May 21, 2020
Branches of biology, G protein-coupled receptors, Protein families, Molecular neuroscience, Orexin receptor, Orexin, RTT, gamma-Aminobutyric acid, GABAA receptor, Insomnia, Hypocretin (orexin) receptor 1, Nemorexant

It is estimated that Asia had the largest number of prevalent cases in 2017 (675.7 million cases).

Key Points: 
  • It is estimated that Asia had the largest number of prevalent cases in 2017 (675.7 million cases).
  • The approved drugs in the insomnia space target GABA-A receptor, hypocretin/orexin receptor, chloride channel 2, chloride, melatonin receptor, histamine H1 receptor, and potassium channels.
  • Germany leads the major European markets, while Japan has the top spot in Asia.
  • Takeda leads the industry sponsors with the highest overall number of clinical trials for insomnia, followed by Merck & Co.

Protecting a Most Precious Asset: GABA Proved to Fortify Cognitive Health in Human Trials

Retrieved on: 
Tuesday, March 31, 2020
Alternative medicine, General Health, Fitness & Nutrition, Health, Branches of biology, Neuroscience, Neurochemistry, Neurotransmitters, Amino acids, Molecular neuroscience, Biology of obsessive–compulsive disorder, gamma-Aminobutyric acid, Aminobutyric acid, gamma-Amino-beta-hydroxybutyric acid, GABBR1

They want to have agency over the state of their mental health as they age, as they do their physical health.

Key Points: 
  • They want to have agency over the state of their mental health as they age, as they do their physical health.
  • The benefits of the naturally-occurring amino acid neurotransmitter GABA [-Aminobutyric acid], found across a range of healthful foods, have never really been in doubt.
  • It has long been known that a decreased systemic level of GABA is associated with the presence of Parkinsons disease, epilepsy, Huntingtons chorea, Alzheimers disease, and schizophrenia.
  • The current studies published by Pharma Foods International offer the promise that a naturally-occurring, naturally derived supplement, GABA, may lead the way.